Dublin, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "The Overview of Japanese Generic Drug Market" report to their offering. This report talks about the overview of Japanese generic drug market.
The readers will understand overall climate surrounding generic market in Japan. The report covers related regulations, generics's share in Japan, market size, primary makers, market trend, and updated situation about biosimilars and authorized generics. The share of generics in the prescription drugs market has been dramatically increasing in terms of both volume and value. The recent volume share was 60.1% in the 2nd quarter in 2016. This increase has been particularly pronounced since 2007 due to government measures devised to increase the use of generics. Key Topics Covered: 1. Summary 2. Definition of Generic Drugs 3. Laws and Regulations Pertaining to Generics 4. NHI Drug Price 5. Share of Generics in Prescription Drugs Market 6. Market Size 7. Principal Industry Association 8. Sales of Major Japanese Generic Companies 9. Primary Generic Manufacturers 10. Overview of Leading Japanese Generics Companies 11. Current Market Environment Conditions 12. Considerations by Company Type 13. Government Measures to Promote the Use of Generics 14. Biosimilars 15. Authorized Generics 16. Future Outlook Companies Mentioned
- Actavis
- Boehringer Ingelheim
- Daiichi Sankyo
- Hospira
- Lupin
- Meiji
- Mochida
- Mylan
- Nichi-Iko
- Nippon Chemiphar
- Nippon Kayaku,Kissei
- Ohara
- Sandoz
- Sanwa
- Sawai
- Teva
- Towa
- Zydus
For more information about this report visit http://www.researchandmarkets.com/research/fp...verview_of
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Generic Drugs
